Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Syndax Pharmaceuticals (NASDAQ: SNDX) announced that CEO Michael A. Metzger will participate in a panel discussion focused on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference. The panel is scheduled for Thursday, December 5, 2024, at 11:00 a.m. ET. A live webcast will be available on the company's website investor section, with a replay option available for a time.
Syndax Pharmaceuticals (NASDAQ: SNDX) ha annunciato che il CEO Michael A. Metzger parteciperà a una discussione di gruppo incentrata su meccanismi innovativi in oncologia durante il Citi 2024 Global Healthcare Conference. Il panel è programmato per giovedì 5 dicembre 2024, alle 11:00 ET. Sarà disponibile una diretta streaming sul sito web dell'azienda nella sezione dedicata agli investitori, con la possibilità di rivedere l'evento successivamente.
Syndax Pharmaceuticals (NASDAQ: SNDX) anunció que el CEO Michael A. Metzger participará en un panel de discusión centrado en nuevos mecanismos en oncología en la Citi 2024 Global Healthcare Conference. El panel está programado para el jueves 5 de diciembre de 2024, a las 11:00 a.m. ET. Se dispondrá de una transmisión en vivo en la sección para inversores del sitio web de la empresa, con una opción de repetición disponible posteriormente.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 CEO Michael A. Metzger가 Citi 2024 Global Healthcare Conference에서 종양학의 새로운 메커니즘에 관한 패널 토론에 참여할 것이라고 발표했습니다. 패널은 2024년 12월 5일 목요일 오전 11시 (동부 표준시)에 예정되어 있습니다. 회사 웹사이트의 투자자 섹션에서 생중계를 시청할 수 있으며, 나중에 재생 옵션도 제공됩니다.
Syndax Pharmaceuticals (NASDAQ: SNDX) a annoncé que le PDG Michael A. Metzger participera à une discussion en panel axée sur de nouveaux mécanismes en oncologie lors de la Citi 2024 Global Healthcare Conference. Le panel est prévu pour le jeudi 5 décembre 2024 à 11h00 ET. Un webinaire en direct sera disponible sur la section investisseurs du site Web de l'entreprise, avec une option de rediffusion disponible par la suite.
Syndax Pharmaceuticals (NASDAQ: SNDX) gab bekannt, dass CEO Michael A. Metzger an einer Podiumsdiskussion über neuartige Mechanismen in der Onkologie auf der Citi 2024 Global Healthcare Conference teilnehmen wird. Die Diskussion ist für Donnerstag, den 5. Dezember 2024, um 11:00 Uhr ET geplant. Eine Live-Übertragung wird im Investorensegment der Unternehmenswebsite verfügbar sein, mit einer Wiederholungsoption zu einem späteren Zeitpunkt.
- None.
- None.
A live webcast of the panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-citi-2024-global-healthcare-conference-302316980.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When is Syndax (SNDX) presenting at the Citi 2024 Global Healthcare Conference?
What topic will Syndax (SNDX) discuss at the Citi 2024 Healthcare Conference?
How can investors access Syndax's (SNDX) panel discussion at the Citi Conference?
